Biotech Stock Still 700%: What Investors Should Do Today
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
Tackling unexpected financial costs starts with a clear plan and small, steady changes you can implement today.
24,369 articlesA biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
The Federal Reserve left policy unchanged and raised its inflation forecast for 2026, shaking up expectations for cry...
A federal jury found Elon Musk liable for misleading investors ahead of the Twitter acquisition. The ruling raises qu...
Billionaire donors are steering college hoops beyond winnings, fueling facilities, NIL deals, and recruiting as the S...
When a director sells shares after a sharp gain, it can spark questions about the stock’s future. This article breaks...
Goldman Sachs upgrades Verizon with a higher price target as the carrier commits to a new reporting framework and ong...
Tower Semiconductor is navigating a critical inflection point as it scales SiPho production and expands in Japan, wit...
VCR is down about 9% year-to-date, but nearly 40% of its holdings sit in Amazon and Tesla, reshaping the fund’s risk ...
The National Association of Realtors says its policies already align with HUD's new guidance on discussing neighborho...
A midstream-focused energy ETF aims to deliver reliable income through toll-road style fees rather than volatile comm...
As AI accelerates, investors face a long-term choice between NVDA and AMD. This piece weighs profitability, growth, a...
A major investor disclosed a $46 million stake in a Goldman Sachs BDC, signaling selective confidence in a sector fac...